Weekly Investment Analysts’ Ratings Updates for United Therapeutics (UTHR)

by · The Cerbat Gem

Several analysts have recently updated their ratings and price targets for United Therapeutics (NASDAQ: UTHR):

  • 5/21/2026 – United Therapeutics had its “buy” rating reaffirmed by TD Cowen.
  • 5/7/2026 – United Therapeutics was given a new $516.00 price target by Morgan Stanley.
  • 5/7/2026 – United Therapeutics was upgraded by Wells Fargo & Company from “equal weight” to “overweight”. They now have a $735.00 price target on the stock, up from $575.00.
  • 5/7/2026 – United Therapeutics had its price target lowered by Royal Bank Of Canada from $707.00 to $701.00. They now have an “outperform” rating on the stock.
  • 4/10/2026 – United Therapeutics had its price target raised by Morgan Stanley from $471.00 to $519.00. They now have an “equal weight” rating on the stock.
  • 4/10/2026 – United Therapeutics is now covered by Raymond James Financial, Inc.. They set an “outperform” rating and a $700.00 price target on the stock.
  • 4/9/2026 – United Therapeutics is now covered by Raymond James Financial, Inc.. They set a “moderate buy” rating on the stock.
  • 3/31/2026 – United Therapeutics had its price target raised by HC Wainwright from $600.00 to $660.00. They now have a “buy” rating on the stock.
  • 3/31/2026 – United Therapeutics had its price target raised by Wells Fargo & Company from $486.00 to $575.00. They now have an “equal weight” rating on the stock.
  • 3/31/2026 – United Therapeutics had its price target raised by Bank of America Corporation from $569.00 to $626.00. They now have a “neutral” rating on the stock.
  • 3/30/2026 – United Therapeutics had its price target raised by TD Cowen from $575.00 to $660.00. They now have a “buy” rating on the stock.
  • 3/23/2026 – United Therapeutics had its price target raised by Wells Fargo & Company from $466.00 to $486.00. They now have an “equal weight” rating on the stock.

Insider Activity

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $567.31, for a total transaction of $5,673,100.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,708,543.56. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $562.82, for a total value of $4,671,406.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $25,423,705.04. The trade was a 15.52% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 559,913 shares of company stock worth $311,962,531. 8.60% of the stock is owned by company insiders.

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Featured Articles